Peptides have become a favorite of longevity and optimization podcasts, and USA TODAY looks at where those claims go wrong.
Recap by typeshit. Post by USA TODAY on X.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
The telehealth company is also adding blood testing services alongside the lower costs for its compounded GLP-1 options.
Huberman says verified, US-made sourcing would change the peptide market, and wonders which compounds beyond GLPs would qualify.
A general explainer on why the body holds onto its large fat reserves even though they carry tens of thousands of calories.
Oral Wegovy fell to about 173,500 weekly prescriptions and Foundayo rose to 60,151. Novo also eyes 15 to 20% yearly GLP-1 growth in India.
9:11
Physician Dr Almerie talks through retatrutide and the effects it may have past the number on the scale.
Loading…